Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity
Launched by MAHIDOL UNIVERSITY · Jun 24, 2015
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
Randomized controlled trial comparing efficacy of magnesium preloading versus normal saline for prevention of acute and chronic nephrotoxicity of cisplatin.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years
- • Eastern Cooperative Oncology Group score 0-2
- • First Diagnosed Head and neck cancer and plan for treatment with cisplatin
- • Serum creatinine ≤1.5 mg/dl or eGFR≥60(ml/min/1.73 m2)
- Exclusion Criteria:
- • Prior treatment with cisplatin before randomization
- • Uncontrolled concurrent disease
- • Pregnancy
About Mahidol University
Mahidol University, a premier institution in Thailand, is dedicated to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the university leverages its extensive expertise in medical and health sciences to facilitate rigorous scientific investigations aimed at improving patient care and public health outcomes. With a commitment to ethical practices and collaboration, Mahidol University fosters multidisciplinary approaches, engaging a diverse array of researchers and healthcare professionals to drive meaningful advancements in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkok, , Thailand
Patients applied
Trial Officials
Arkom Nongnuch, MD
Principal Investigator
Ramathibodi hospital, Mahidol university
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials